Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways

BACKGROUND: Chronic heart failure (CHF) is the end stage of cardiac disease with a 5-year mortality rate reaching 50%. Simvastatin is an antioxidant with lipid-lowering effects, which is commonly used to treat CHF. Resistance training is a nondrug treatment for CHF and exerts a positive effect on bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaowen, Yan, Kaiyun, Wen, Cuifeng, Wang, Jiaqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934205/
https://www.ncbi.nlm.nih.gov/pubmed/35356068
http://dx.doi.org/10.1155/2022/8430733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934205/
https://www.ncbi.nlm.nih.gov/pubmed/35356068
http://dx.doi.org/10.1155/2022/8430733

Ejemplares similares